Energy Manager
46 minutes ago
Looks like 4 purchases, probably options, purchased for Vern and Michael Kornelson, Sieck, and Edco Partners.
Interesting to note that all were Indirect Purchases as Filed in Table 1 section 6, indicated with an I, and Edco Partners was a Direct Purchase, indicated with a D. Not sure how meaningful that actually is. I, honestly, am not familiar with the form, other that it indicates a Purchase (A) or Sale (D). Also, not that it matters, but they filed the wrong ticker symbol in Edco's filing as LCLC.
Lifeloc Technologies, Inc. (LCTC) is a subsidiary of EDCO Partners LLLP. On July 23, 2024, EDCO Partners purchased 210,000 shares of Lifeloc Technologies' common stock for $3.80 per share, bringing their total ownership to 2,065,319 shares. EDCO Partners also serves as a director for Lifeloc Technologies.
pdicamillo1
2 weeks ago
Also keep in mind that Sandia National Laboratories is operated and managed by National Technology and Engineering Solutions of Sandia, LLC., a wholly owned subsidiary of Honeywell International, Inc.
The most logical partnership with Lifeloc might actually be Sandia (Honeywell). The Lifeloc and Sandia licensing agreement in 2016 allowed Lifeloc to acquire the exclusive rights to develop, manufacture and market Sandiaβs patented SpinDx technology for the detection of drugs of abuse.
Honeywell has a market cap of $140 billion (14,000 times that of Lifeloc)
Honeywell has revenues of $36.9 billion (4,000 times that of Lifeloc)
I would love to see Honeywell and/or Sandia partner with Lifeloc when the SpinDx technology has proven itself. Once again, peanuts for a company like Honeywell who is the 115th largest.
pdicamillo1
2 weeks ago
SoToxa Mobile Test System - Due Diligence:
The SoToxa Oral Fluid Mobile Test System is designed for rapid drug screening and detection in oral fluid. With test results in minutes, this handheld analyser is lightweight, compact, and easy to useβconvenient for drug screening at the roadside in any type of vehicle or in the workplace.
SoToxa is owned by Abbott - Abbott is committed to providing reliable, innovative and value-focused drug and alcohol abuse screening products and laboratory services to our customers around the world. They are the #1 GLOBAL PROVIDER OF RAPID, POINT OF CARE TESTS and #1 GLOBAL TOXICOLOGY WITH RAPID SCREENING, LABORATORY SERVICES, & PROGRAM MANAGEMENT.
Abbott has yearly revenue of $40 Billion (That is 4,000 times that of Lifeloc)
Abbott has a market cap of $182 Billion (That is 19,000 times that of Lifeloc)
The SoToxa device has its fair share of negative publicity:
https://www.acsh.org/news/2023/07/17/kansas-flawed-dui-drug-screen-isnt-better-nothing-its-worse-17194
"SoToxa, Abbott's hand-held analytical device can rapidly detect and identify common drugs in saliva but gives no information about the amount of drug present. I predict this will cause all kinds of problems"
https://www.mlive.com/public-interest/2021/03/positive-roadside-drug-tests-wrong-nearly-24-of-the-time-in-michigan-pilot-data-shows.html
"Of 934 positive test results recorded by the SoToxa devices in Michigan between October 2019 and Sept. 30, 2020, nearly a quarter, 222, were later proven wrong by blood tests, according to analysis reported to legislators in January. Cumulatively, nearly 11% of all tests produced incorrect results, either false positives or false negatives that didnβt match findings from follow-up blood tests. The devices were much less accurate when detecting other drugs. The test data shows 65% of SoToxa test samples that issued positive results for opiates were wrong when compared to blood tests. More than 30% of the positive test findings for cocaine and amphetamines were also later discredited by blood tests. The positive findings for benzodiazapene were wrong 60% of the time."
If the SpinDx can prove accuracy and reliability, it really is a game changer. Abbott is just another example of a company that could easily acquire Lifeloc and immediately start producing results that would make it worth the acquisition. This SoToxa device doesn't really seem that accurate and it probably does more revenue just from this device than Lifeloc does as a company. I still believe that Lifeloc could be a great acquisition for one of these big boys that can see the potential and bring it up to speed and start making things happen.
Energy Manager
2 weeks ago
I am certain that Draeger's Drug Test 5000 is only qualitative.
Directly from the Draeger web site - Owner's Manual:
3.3 Confirmation of results
The DrΓ€ger DrugTest 5000 test system is a qualitative measurement procedure. For a confirmed result, a second sample must be taken and analyzed
by an accredited laboratory.
Take the second sample with a collection system suitable for saliva samples.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
It basically will tell you +/- for a specific drug. The tester has to take a second saliva sample, and ship it to a lab for further testing if +, to determine the numeric, or quantitative level. Lifeloc's device will give you a numeric reading for THC in ng/ml on site, within minutes. That reading will distinguish immediately if the subject is above, or below the legal cut-off limit for the state, country, or municipality - just like an alcohol breathalyzer would give a value, such as 0.10%.
The US Department of Transportation has established a limit of 4 ng/ml for THC. Other countries are now establishing similar cut-off limits for THC as well.
The DDT5000 is designed to be used at the roadside or after arrest, much akin to the portable breath test (PBT) devices used for alcohol testing. Unlike the PBT, the DDT5000 does not provide any numerical reading, limiting the utility of the devices to a roadside "screening" as opposed to a quantitative device. Even a positive result still requires confirmatory testing1. The DDT5000 only provides a qualitative result of a positive or negative sample, and Draeger, Inc. states in its manual that in order to obtain a confirmed analytical result, a more specific alternate chemical method is needed, such as Gas Chromatography/Mass Spectrometry. Thus, Draeger suggests that a second saliva sample be obtained and analyzed by an accredited laboratory.
Energy Manager
2 weeks ago
The main, and significant difference between the Draeger device, and Lifeloc, is that Lifeloc's Spin Dx device gives a "Quantitative" measurement, whereas Draeger's device is simply Pass/Fail - Huge Difference.
An Important Note:
We need to differentiate a screening device from an evidentiary device.
In a screening device, analytical results are merely qualitatively identified as, in the case of the DrΓ€ger
5000 - POSITIVE or NEGATIVE (present or not present to a sufficient amount or, as in the case of breath
alcohol screening devices - Pass, Warn, or Fail).
A device is considered qualitative because no amount, concentration or quantity is measured β it
merely detects the presence of a specific substance in the test sample.
In a more complex evidentiary or quantitative device, the amount of the thing being measured is also
displayed (i.e, - 0.05 grams per 100mL, or 13 nanograms per millilitre, etc.). This degree of
sophistication would require substantially more calibration and control for reliable testing.
By identifying the DrΓ€ger 5000 as a screening device, DrΓ€ger is signifying the inherent limitations of the device, and that limitation should be respected as we examine its performance characteristics.
pdicamillo1
2 weeks ago
You know what's a bit crazy. Drager spends $325 million a year on R & D costs and has revenue of $3.3 billion/year. For less than 1% of its revenue and 10% of its R & D expenditure they could acquire Lifeloc and own all the patents, technology, alcohol breathalyzer business, RADAR, SpinDX, etc.
That's a company that could really start making moves with all that's there at Lifeloc. Feels like it would work out really well for Drager with such a small investment for its acquisition.
Energy Manager
3 weeks ago
US Department of Transportation set the THC Cutoff limit at 4 ng/ml, now Germany is following along, as well as other countries, in setting limits for driving under the influence of cannabis... I wonder how they are going to test these drivers to determine their THC levels...? If only a company could develop such a device, they could make hundreds of millions of dollars, and possibly save limitless lives.
https://aussiedlerbote.de/en/federal-council-approves-cannabis-limit-for-driving/
pdicamillo1
3 weeks ago
Ohio law enforcement could soon perform rapid drug tests during OVI stops:
https://www.news5cleveland.com/news/local-news/ohio-law-enforcement-could-soon-perform-rapid-drug-tests-during-ovi-stops
"The bill would allow law enforcement officers to perform new fast-result drug tests in the field, among other things."
βThey can do a swab of your mouth, test your saliva, and get an immediate result to know if you're under the influence of drugs or not,β Plummer said. βSo, this is a game changer. Itβs no longer having to take blood or urine and take it to the crime lab and wait months for the results. This is an immediate test.β Cuyahoga County Sheriff Harold Pretel said having saliva testing technology would be a game changer for the department.
The article fails to mention the name of the drug testing company or type of device they are using. But it does show the need for saliva based drug tests are increasing dramatically.
pdicamillo1
4 weeks ago
NIST Partners With the Gates Foundation to Develop Breathalyzers for Malaria and Tuberculosis:
https://www.einnews.com/pr_news/723094603/nist-partners-with-the-gates-foundation-to-develop-breathalyzers-for-malaria-and-tuberculosis
"Breath-based diagnostics may soon be used to identify or monitor the progression of a wide range of conditions and diseases, including liver disease, multiple sclerosis and cancer."
In recent years, scientists have begun identifying biomarkers in human breath β a so-called breathprint β that indicate when someone's been infected by malaria or TB. By developing sensors that can detect these biomarkers, researchers hope to build low-cost, easily deployable breathalyzers that can be used globally.
So much potential for a wide array of tests and conditions.
Energy Manager
1 month ago
Looks like their sales are now exceeding pre-pandemic levels, which is noteworthy in itself. Here's a copy of their PowerPoint presentation. https://lifeloc.com/pub/media/pdf/shareholderMeeting2024.pdf
Without getting too far ahead of ourselves, I'm curious as to what they have in mind when they state they plan on developing discs for testing beyond drugs of abuse? Is it medical testing for disease or viruses, such as Covid? Or could they be thinking rapid detection of biological agents - such as Anthrax, Ricin, Ebola, Botulism, Plague, Smallpox. Tularemia, etc...?
Looking far down the road, this could open a plethora of new revenue streams, including Homeland Security, Military, etc. I don't want to speculate too much on this now, just interesting that they included it in this year's Annual Report.
Another thing I don't want to speculate too much on, but interesting to note, that it sounds like they brought up Draeger more than once during the meeting. Draeger, a direct competitor of Lifeloc, has a Market Cap of nearly 1 Billion Dollars, is in 190 countries, and has over 16,000 employees. I have followed Lifeloc, and it's competitors, for many years, and can tell you that Draeger is keeping a close eye on the Marijuana/Drugs of Abuse Testing Sector, as well as the developments of Lifeloc's SpinDx device. I would not be surprised to hear more about discussions between these two companies in the future.
Energy Manager
1 month ago
Great synopsis! Thanks for taking the time to do this. All very positive.
Line of credit is much better than dilutive financing ,but as I stated before, if Lifeloc could use extra cash to accelerate roll-out, marketing, etc., an extra 10 million + dollars in equity financing could be looked at very positively - as long as it was done with favorable terms. Quite honestly, if someone wanted to buy $10,000,000 worth of stock on the open market, it simply couldn't happen. So, Lifeloc management needs to keep shareholders in mind in regard to any equity financing. By this, I mean no death spiral financing, where every month, the company would issue shares of stock to the investor, at below market prices.
If I were management, I would consider this, but only do the deal at a price within 10% of it's current closing price, in one lump sum. This would also possibly achieve adding more liquidity in the trading of the stock, and possibly help meet criteria on eventually listing on a better exchange, such as the NASDAQ.
Everything else you summarized is very exciting, and we, as shareholders, should take a deep breath, and exhale. I'm sure there will be bumps in the road, but there is definitely beginning to be some light at the end of the tunnel.
pdicamillo1
1 month ago
Lifeloc Technologies 2024 Annual Conference call notes:
Profitable and cash flow positive to fund growth
Using full resources to pursue growth of the drug detection SpinDx device
Lifeloc still sees the company growing to $100 million and beyond
Spin DX technology utilized beyond drug testing. Over 2 million spent on research so far.
Recurring revenue from supplies and service should follow the increases in Alcohol device equipment sales
L series focus for core Alcohol product line
Rapid drug testing is best opportunity to grow revenue by multiples 2x, 5x, 10x is foreseeable
Legalization of marijuana just increases the demand for drug testing equipment
Sandia prototype with disk - real live functional prototype with firmware and inflection device
Current analysis time down to 15 minutes with 8-10 minutes expected in the near future
SpinDx demonstrated in lab to detect panel of drugs in saliva or blood
First US Utility and PCT patents filed for SpinDx technology
Testing beyond testing for drugs of abuse
Beta testing to begin Q4 this year
First product release will be a reader with collection kit
Questions:
1. 5 n/g spiked solutions. 10 n/g human saliva. Every reason to believe to get down to 5 n/g - that is the goal. We believe we will hit that target but still has yet be demonstrated. Some jurisdictions have taken 5 n/g 4 n/g or zero tolerance. Firmware will be able to call up different jurisdictions.
2. Beta testing β expected 4th quarter 2024
3. Not satisfied. No pre-market hype. Be careful to not hype so far in advance to lose credibility. Functional prototype was shown at the meeting. The time is ripe to start letting people know this product is coming.
4. On track to begin commercialization of saliva testing. No expected timeline for breath systems. Still a number of unknowns.
5. Cash is dropping and looking into ways to replenish. Close on a line of credit this month to plug a hole in cash.
6. Working on exact pricing strategy. Competitive to Draeger. Priced slightly under the Draeger device. $25 collection device. Price aggressively. Good margin. First quarter rollout small profit contribution is expected but grows rapidly.
7. US DOT issued rules for saliva testing but no methodology. Expect to satisfy the customers. Flexible and customizable software and firmware to do that.
8. Shareholder who attended the meeting and was in the room has been buying stock which is the reason for the large share prints recently.
9. Social media awareness - time is ripe to get some help for awareness.
10. Wayne agrees and is not satisfied with the current market cap. Company inherently more valuable now than in 2014. Tons of investment into SpinDX. Market value is unreasonably low. Confident that this is coming out next year.
Open floor to shareholder questions.
1 version of the SpinDx. Handheld device 2025. They have shown the SpinDx device only to a small group.
% of R and D expense - 65% towards SpinDx.
Design of disk and collection device are currently outsourced and are still being worked on by third parties.
Full panel of drugs - right around $25. Address every segment of the market depending on what's needed. Firmware will read the cutoff. 5 n/g vs. 25 n/g. Technology is readily available to be put into the firmware.
Other uses in addition to drug detection - Drugs of abuse current license. Performance enhancing drugs, food safety, human diagnostics are all additional sectors of the market that could be addressed, enormous market potential.
Expectation loaded with the reagents - will get there quickly with optimization and tuning.
How confident about testing and commercialization. Confidence is growing . We can identify everything that needs to happen. Reader is functional. Saleable today but they still need molds and design finalization. No longer any research that needs to be discovered - Just implemented.
Incremental to existing customer base - sales and marketing process - same customers base. Loyal customer base. Beta testing through current customers.
Sandia exclusive patent - modest annual fee to keep the license in addition to % of revenue from product. Lasts until last patent expires. 15 years left. The license of the device supports US manufacturing.
Competition currently on the market. Drager, Sotaxa saliva tester pass/fail - numbers for small panel of drugs. Hound labs - collect breath and send to lab. Not immediate. Days turnaround. Compete with Drager on price - flexibility to change drug panels and cutoffs.
Exceeding $100 million - 5 year achievable goal. Reasonable objective. Alcohol testing worldwide. Lifeloc currently has 4-5% share of alcohol market. Rapid drug testing $4 billion market. 2.5% chunk of that market seems reasonable and puts them at $100 million in additional revenue.
No sales effort to date. Just previews. Will be a dedicated position in marketing.
Sales in all 50 states. Workplace every state. Law enforcement - 25 states
Line of credit established - favorable terms - not expensive money. Minimize shareholder dilution.
No red flags in SpinDx rollout. On track with SpinDx. Reasonable reason to believe that it will succeed in the marketplace. Market acceptance is unknown. Better margin on consumables than the device. Subscription element - making sure firmware is up to date is critical for jurisdictions.
Accelerate to market faster with more cash - they are going as hard as they can go. Question comes from current investor β Would $5 - $20 million in capital help to speed up the Spin DX production and sales. Current investor has ties to a group that would be willing to invest upwards of $5-20 million in Lifeloc if it could be deplorable in a useful way to speed up production, sales, marketing, etc. Call ended with Lifeloc organizing a follow up meeting with this potential investor group.
Energy Manager
1 month ago
Yes, feel free to ask anything you feel pertinent. I am having some remodeling done on my home in Florida, and will be traveling a lot this week, between there, and my home up North, so I may not be available to attend the meeting. Hopefully it will be recorded, and I can listen in at a later time.
Energy Manager
1 month ago
Well the annual shareholders meeting is on Wednesday, and I put in my proxy vote, not that it matters... I wonder if we will get any material news next week, or just same old generic meeting? I'm going to try to listen in, but not sure of my schedule.
A few questions I would like to ask are:
1. The current accuracy of the device can detect THC down to 10ng/ml, have you made improvements, and what is the end point goal in terms of accuracy?
2. You previously stated you had begun human trials, and had a framework in place to begin Beta testing of the saliva based system. Where do you currently stand as far as this Beta testing, has it begun? Any insight here?
3. In regard to marketing, and brand awareness, Lifeloc seems to be very complacent with their achievements thus far, and the share price suffers due to this. Do you have a plan in place to increase marketing, social media awareness, and attract investors ?
4. Do you still feel that you are on track to begin commercialization of the saliva based, SpinDx device next year, and if so, do you have an expected timeline to integrate this system with the LX9 Breathalyzer.
5. Do you feel that you have sufficient means to continue funding the development of this device organically, without the need to raise cash through borrowing or Equity financing?
6. What do you value the Saliva based SpinDx device at in terms of yearly sales forecasts after commercialization? What price point do you expect to come in at for the device, and any associated hardware/software. What is an estimated price of the consumable disks, and will these be manufactured by Lifeloc, or a third party.
7. Do you expect that this device will meet the requirements of most modern registration standards set in place by the US, and abroad?
Investors have been patient for many years now, going all the way back to 2014, when Lifeloc was awarded a $250,000 grant by the state of Colorado, to develop a marijuana breathalyzer. An investment in Lifeloc common stock in 2014 would be worth half now, at best, and probably much less. Lifeloc's Market Cap is currently much lower than it's peers competing in the same market. It's time to bring this company, it's common stock, and it's investors to the forefront.
Energy Manager
1 month ago
Yes, an improvement in the equipment's accuracy would be a huge step forward. I worked as a lab tech for Dupont, in their electronic imaging systems department, and know that not only does their technology have to be accurate, but it has to be accurate in all environmental conditions, due to the fact that they will be testing roadside - in climates all over the world. Things like temperature, humidity, etc. can definitely impact accuracy of equipment. I can say with some certainty, that this is one of the obstacles they are dealing with...
Energy Manager
2 months ago
My guess is that it was a balancing of shares for the MM's - hopefully in preparation for some good things to come. I noticed that after the 25,000 share trade, INTL was running the show for a day or two, whereas NITE had been the MM in charge up to that point.
As far as not getting your orders filled, you can always call your broker, and see if they can do anything for you. I had the same thing occur years ago, trading a stem cell stock. My trade never executed, even though thousands of shares traded well above, and below the limit price. I called my broker, they called the specialist, and my trade executed after hours at my original limit price, even though the closing price was well above my buy limit order.
As far as social media goes, I agree Lifeloc is missing the boat. I have owned several businesses, and I currently own a garden center and seafood business. Social media has been a huge, and very inexpensive way to advertise and build your brand. If we finally get some good news, it will be easy for the few of us on this board, to hit up Twitter and Facebook stock groups to spread the word. I've tried this in the past, and at least tried to get people to put it on their radar, but without any substantial news, traders just move on to "stocks in the news..."
pdicamillo1
2 months ago
Lifeloc has a job post for Research Laboratory Technician:
Lifeloc Technologies, a leader in commercial and professional breathalyzer testing technology, is looking to hire a Research Technician to support research, development, and commercialization of its latest product for detection of controlled substances. This position will support research to develop and validate tests for this exciting new technology in preparation for commercial launch.
Specifically, the Laboratory Technician will be expected to aid in the development and testing of antibody-based reagents and equipment, establish tests with the project manager for validation of the device, and then assist company personnel with scale-up processes for manufacturing and reagent packaging for final commercialization.